Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis
Early and aggressive reduction of low-density lipoprotein cholesterol (LDL-C) has been linked to improved cardiovascular outcomes. Despite proven efficacy of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies in lowering LDL-C and reducing risk of cardiovascular events, access to PCSK9i medications in the United States (US) has been limited for many eligible patients, leading to either delayed or no utilization.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Laura Martinez, Jasjit Kaur Multani, Kainan Sun, Bethany A Kalich, Margot Lisa Miglins, Eduard Sidelnikov, Usman Baber Tags: Lipid Management through Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Databases & Libraries | Drugs & Pharmacology | Heart | Lipidology | USA Health